Profile of respiratory syncytial virus prefusogenic fusion protein nanoparticle vaccine

References

• Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–958. PMID: 28689664 PMCID: PMC5592248.
   PubMed Web of Science ®Google Scholar
• Shi T, Arnott A, Semogas I, et al. The etiological role of common respiratory viruses in acute respiratory infections in older adults: a systematic review and meta-analysis. J Infect Dis. 2020;222(7):S577-S583 PMID: 30849176 PMCID: PMC7107439.
   Google Scholar
• Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(Supplement_7):S563-S569 PMID: 30880339.
   Google Scholar
• Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261–269. PMID: 30880339.
   PubMed Web of Science ®Google Scholar
• Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–1555. PMID: 20399493; PMCID: PMC2864404.
   PubMed Web of Science ®Google Scholar
• Haynes AK, Prill MM, Iwane MK, et al. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus–United States. Jul 2012-Jun 2014. MMWR Morb Mortal Wkly Rep. 2014. 63(48):1133–1136. Erratum in: MMWR Morb Mortal Wkly Rep. 2014Dec12. 63( 49): 1181. PMID: 25474034; PMCID: PMC4584603.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK et al., The burden of respiratory syncytial virus infection in young children. N Engl J Med PMID: 19196675; PMCID: PMC4829966. 2009;360(6): 588–598.
   PubMed Web of Science ®Google Scholar
• Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541–545. PMID: 10470697.
   PubMed Web of Science ®Google Scholar
• Mejias A, Wu B, Tandon N, et al. Risk of childhood wheeze and asthma after respiratory syncytial virus infection in full-term infants. Pediatr Allergy Immunol. 2020. 31(1):47–56. Epub 2019Oct23. PMID: 31566811.
   PubMed Web of Science ®Google Scholar
• Martinez FD.Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J. 2003. 22. 2 Suppl): S76-82. PMID: 12671456.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets. 2012;12(2):98–102. PMID:22335500.
   PubMedGoogle Scholar
• Rhe IMpact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998. 102(3 Pt 1):531–537. PMID: 9738173.
   Web of Science ®Google Scholar
• Lieberthal AS, Meer HC. AAP updates guidance on use of palivizumab for RSV prophylaxis. AAP News. 2014; 35(8) :1 10.1542/aapnews.2014358-1.
   Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434. PMID: 4305198.
   PubMed Web of Science ®Google Scholar
• Murphy BR, Sotnikov AV, Lawrence LA, et al. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine. 1990;8(5):497–502. PMID: 2251875.
   PubMed Web of Science ®Google Scholar
• Waris ME, Tsou C, Erdman DD, et al. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol. 1996;70(5):2852–2860. PMID:8627759; PMCID: PMC190142.
   PubMed Web of Science ®Google Scholar
• Connors M, Giese NA, Kulkarni AB et al., Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol PMID: 8035532; PMCID: PMC236482. 1994;68(8): 5321–5325.
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002;196(6):859–865. PMID: 12235218 PMCID: PMC2194058.
   PubMed Web of Science ®Google Scholar
• Dreizin RS, Vyshnevetskaia LO, Bagdamian EE, et al. Experimental RS virus infection of cotton rats. A viral and immunofluorescent study. Vopr Virusol. 1971;16(6):670–676. PMID: 5141611.
   PubMedGoogle Scholar
• Prince GA, Jenson AB, Horswood RL, et al. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol. 1978;93(3):771–791. PMID: 362946 PMCID: PMC2018360.
   PubMed Web of Science ®Google Scholar
• Collins PL, Hill MG, Camargo EN, et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5ʹproximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Nat Acad Sci. 1995;92(25):11563–11567. PMID: 8524804 PMCID: PMC40442.
   PubMed Web of Science ®Google Scholar
• Englund JA, Glezen WP, Piedra PA. Maternal immunization against viral disease. PMID: 9711788 Vaccine. 1998;1614:1456–1463.
   PubMed Web of Science ®Google Scholar
• Swamy GK, Heine RP. Vaccinations for pregnant women. Obstet Gynecol. 2015 Jan;125(1):212–226. PMID: 25560127; PMCID: PMC4286306.
   PubMed Web of Science ®Google Scholar
• Hause AM, Avadhanula V, Maccato ML et al., A cross-sectional surveillance study of the frequency and etiology of acute respiratory illness among pregnant women. J Infect Dis PMID: 29741642 PMCID: PMC7107407. 2018;218(4): 528–535.
   PubMed Web of Science ®Google Scholar
• Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine. 2003 Jul 28;21(24):3465–3467. PMID: 12850361.
   PubMed Web of Science ®Google Scholar
• WHO Vaccine Pipeline Tracker. [(accessed on 2020)] Dec 15; Available online: https://docs.google.com/spreadsheets/d/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM/pubhtml#.
   Google Scholar
• Biagi C, Dondi A, Scarpini S, et al. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines (Basel). PMID:33187337; PMCID: PMC7711987. 2020;8(4):672.
   PubMed Web of Science ®Google Scholar
• Karron RA, Luongo C, Mateo JS et al., Safety and immunogenicity of the respiratory syncytial virus vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-seronegative children. J Infect Dis PMID: 31605113; PMCID: PMC7199783. 2020;222(1): 82–91. :.
   PubMed Web of Science ®Google Scholar
• Samy N, Reichhardt D, Schmidt D, et al. Safety and immunogenicity of novel modified vaccinia ankara-vectored RSV vaccine: a randomized phase I clinical trial. Vaccine. 2020;38(11):2608–2619. PMID: 32057576.
   PubMed Web of Science ®Google Scholar
• Van Der Fits L, Bolder R. Heemskerk-van der meer m. et al. Adenovector 26 encoded prefusion conformation stabilized rsv-f protein induces long-lasting th1-biased immunity in neonatal mice. npj. Vaccines (Basel). 2020;5(49). PMID: 32566260 PMCID: PMC7293210.
   Google Scholar
• Williams K, Bastian AR, Feldman RA, et al. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion f (ad26.rsv.pref) in adults aged ≥60 years. J Infect Dis. 2020;222(6):979–988. PMID: 32320465.
   PubMed Web of Science ®Google Scholar
• Malkin E, Yogev R, Abughali N et al., Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS One PMID: 24204744; PMCID: PMC3812203. 2013;8(10): e77104.
   PubMed Web of Science ®Google Scholar
• Sadoff J, De Paepe E, DeVincenzo J, et al. Prevention of respiratory syncytial virus infection in healthy adults by a single immunization of ad26.rsv.pref in a human challenge study. J Infect Dis. 2021Jan5. jiab003. Epub ahead of print. PMID: 33400792.
   Google Scholar
• Eaf S, Forleo-Neto E, Geba GP, et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis. 2020. ciaa951. Epub ahead of print. PMID: 32897368.
   PubMedGoogle Scholar
• PATH.org. [(accessed on 2020)] Dec 15; Available online: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/
   Google Scholar
• Afonso CL, Amarasinghe GK, Bányai K, et al.Taxonomy of the order Mononegavirales: update. 2016. Arch Virol. 2016 Aug. 161(8):2351–2360. Epub 2016 May 23. PMID: 27216929; PMCID: PMC4947412. .
   PubMed Web of Science ®Google Scholar
• Liljeroos L, Krzyzaniak MA, Helenius A, et al. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A. 2013Jul2. 110(27):11133–11138. Epub 2013 Jun 17. PMID: 23776214; PMCID: PMC3703984.
   PubMed Web of Science ®Google Scholar
• Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019 Sep 10;366. l5021.PMID: 31506273.
   PubMedGoogle Scholar
• Melero JA, Mas V, McLellan JS. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine. 201711. 35(3):461–468. Epub 2016 Sep 28. PMID: 27692522; PMCID: PMC5189713.
   PubMed Web of Science ®Google Scholar
• Hause AM, Henke DM, Avadhanula V, et al. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PloS One. 2017;12(4): e0175792 PMID: 28414749 PMCID: PMC5393888.
   Web of Science ®Google Scholar
• Tapia LI, Shaw CA, Aideyan LO et al., Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas. PloS One PMID: 24625544 PMCID: PMC3953119. 2014;9(3): e90786.
   PubMed Web of Science ®Google Scholar
• Re D, Rn H, Ma N, et al. Paramyxovirus fusion (F) protein: a conformational change on cleavage activation. Virology. 2001. Mar1. 281. 1):138–150 PMID: 11222104.
   PubMed Web of Science ®Google Scholar
• Zimmer G, Budz L, Herrler G. Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J Biol Chem. Epub 2001 Jun 19. PMID: 11418598. 2001;276(34):31642–31650.
   PubMed Web of Science ®Google Scholar
• Gilman MSA, Furmanova-Hollenstein P, Pascual G, et al. Transient opening of trimeric prefusion RSV F proteins. Nat Commun. 209. 10, 2105. PMID: 31068578 PMCID: PMC6506550.
   Google Scholar
• Mousa JJ, Kose N, Matta P et al., A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol PMID: 28134924 PMCID: PMC5463187. 2017;2(4): 16271.
   PubMed Web of Science ®Google Scholar
• Mousa JJ, Binshtein E, Human S, et al. Human antibody recognition of antigenic site IV on pneumovirus fusion proteins. Subbarao K, ed. PLOS Pathog. 2018;14(2):e1006837. PMID: 29470533 PMCID: PMC5823459.
   PubMed Web of Science ®Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013May31. 340(6136)1113–1117. Epub 2013 Apr 25. PMID: 23618766; PMCID: PMC4459498.
   PubMed Web of Science ®Google Scholar
• Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015Oct14. 7(309):309ra162. PMID: 26468324; PMCID: PMC4672383.
   PubMed Web of Science ®Google Scholar
• Ye X, Iwuchukwu OP, Avadhanula V, et al. Antigenic site-specific competitive antibody responses to the fusion protein of respiratory syncytial virus were associated with viral clearance in hematopoietic cell transplantation adults. Front Immunol. PMID: 30984206; PMCID: PMC6449644 2019;10:706.
   PubMed Web of Science ®Google Scholar
• Ye X, Iwuchukwu OP, Avadhanula V, et al. Comparison of palivizumab-like antibody binding to different conformations of the rsv f protein in rsv-infected adult hematopoietic cell transplant recipients. J Infect Dis. 2018;217(8):1247–1256. PMID: 29365155.
   PubMed Web of Science ®Google Scholar
• Melero JA, Mas V, McLellan JS. Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine. PMID: 27692522 PMCID: PMC5189713. 2017;35(3):461–468.
   PubMed Web of Science ®Google Scholar
• Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol PMID: 27157411 PMCID: PMC5079805. 2016;120:1–14.
   PubMed Web of Science ®Google Scholar
• Moser M, Leo O. Key concepts in immunology. Vaccine. 2010;28:2–13.
   PubMed Web of Science ®Google Scholar
• Pati R, Shevtsov M, Sonawane A. Nanoparticle vaccines against infectious diseases. Front Immunol. Internet]. 2018 [cited 2020 Sep 28];9:2224. Available from: www.frontiersin.org. PMID: 30337923 PMCID: PMC6180194.
   PubMed Web of Science ®Google Scholar
• Simons K, Helenius A, Leonard K. Formation of protein micelles from amphiphilic membrane proteins. Proc Natl Acad Sci. PMID: 214782 PMCID: PMC392951. 1978;75(11):5306–5310.
   PubMed Web of Science ®Google Scholar
• Coleman CM, Liu YV, Mu H et al., Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine PMID: 24736006 PMCID: PMC4058772. 2014;32(26): 3169–3174.
   PubMed Web of Science ®Google Scholar
• Al-Halifa S, Gauthier L, Arpin D, et al. Nanoparticle-based vaccines against respiratory viruses. Front Immunol. 2019. 10. JAN. 1-11. PMID: 30733717 PMCID: PMC6353795.
   PubMed Web of Science ®Google Scholar
• Smith G, Raghunandan R, Wu Y, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. Varga SM, ed. 2012;7(11):e50852. PMID: 23226404 PMCID: PMC3511306.
   PubMed Web of Science ®Google Scholar
• Patel N, Massare MJ, Tian JH, et al. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: structure, antigenic profile, immunogenicity, and protection. Vaccine. 2019Sep24. 37(41):6112–6124. Epub 2019 Aug 12. PMID: 31416644.
   PubMed Web of Science ®Google Scholar
• Calder LJ, González-Reyes L, García-Barreno B, et al. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology. 2000;271(1):122–131. PMID: 10814577.
   PubMed Web of Science ®Google Scholar
• Krueger S, Curtis JE, Scott DR et al., Structural characterization and modeling of a respiratory syncytial virus fusion glycoprotein nanoparticle vaccine in solution. Mol Pharm Epub 2020 Dec 15. PMID: 33322901. 2021;18(1): 359–376.
   PubMedGoogle Scholar
• Fuentes S, Coyle EM, Beeler J et al., Antigenic fingerprinting following primary rsv infection in young children identifies novel antigenic sites and reveals unlinked evolution of human antibody repertoires to fusion and attachment glycoproteins. PLoS Pathog PMID: 27100289 PMCID: PMC4839671. 2016;12(4): 1–24.
   Web of Science ®Google Scholar
• Patel N, Tian JH, Flores R, et al. Flexible RSV prefusogenic fusion glycoprotein exposes multiple neutralizing epitopes that may collectively contribute to protective immunity. Vaccines (Basel). PMID: 33066540; PMCID: PMC7711572. 2020;8(4):607.
   Web of Science ®Google Scholar
• Goritzka M, Makris S, Kausar F, et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J Exp Med. 2015. 212(5):699–714. Epub 2015 Apr 20. PMID: 25897172; PMCID: PMC4419339.
   PubMed Web of Science ®Google Scholar
• Bhoj VG, Sun Q, Bhoj EJ, et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2008. 105(37):14046–14051. Epub 2008 Sep 9. PMID: 18780793; PMCID: PMC2532974.
   PubMed Web of Science ®Google Scholar
• Demoor T, Petersen BC, Morris S, et al. IPS-1 signaling has a nonredundant role in mediating antiviral responses and the clearance of respiratory syncytial virus. J Immunol. 2012. 189(12):5942–5953. Epub 2012 Nov 7. PMID: 23136205; PMCID: PMC3888965.
   PubMed Web of Science ®Google Scholar
• Marr N, Turvey SE, Grandvaux N. Pathogen recognition receptor crosstalk in respiratory syncytial virus sensing: a host and cell type perspective. Trends Microbiol. 2013. 21(11):568–574. Epub 2013 Oct 9. PMID: 24119913; PMCID: PMC4848032.
   PubMed Web of Science ®Google Scholar
• Borchers AT, Chang C, Gershwin ME, et al. Respiratory syncytial virus–a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331–379. PMID: 23575961; PMCID: PMC7090643.
   PubMed Web of Science ®Google Scholar
• Topham NJ, Hewitt EW. Natural killer cell cytotoxicity: how do they pull the trigger? Immunology. PMID: 19689731; PMCID: PMC2747134. 2009;128(1):7–15.
   PubMed Web of Science ®Google Scholar
• Kaiko GE, Phipps S, Angkasekwinai P et al., NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol Epub 2010 Sep 20. PMID: 20855881. 2010;185(8): 4681–4690.
   PubMed Web of Science ®Google Scholar
• Graham BS, Bunton LA, Wright PF et al., Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest PMID: 1909350; PMCID: PMC295511. 1991;88(3): 1026–1033.
   PubMed Web of Science ®Google Scholar
• Liu J, Haddad EK, Marceau J et al., A numerically subdominant cd8 t cell response to matrix protein of respiratory syncytial virus controls infection with limited immunopathology. PLoS Pathog PMID: 26943673; PMCID: PMC4778879. 2016;12(3): e1005486.
   PubMed Web of Science ®Google Scholar
• Morabito KM, Ruckwardt TR, Redwood AJ, et al. Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+ T cells in the lung. Mucosal Immunol. 2017. 10(2):545–554. Epub 2016 May 25. PMID: 27220815; PMCID: PMC5123975.
   PubMed Web of Science ®Google Scholar
• Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol. PMID: 19017987; PMCID: PMC2587004. 2008;181(11):7958–7968.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Openshaw PJ, Askonas BA. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med. PMID: 3262705; PMCID: PMC2189034. 1988;168(3):1163–1168.
   PubMed Web of Science ®Google Scholar
• Schmidt ME, Knudson CJ, Hartwig SM et al., Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. PLoS Pathog PMID: 29293660; PMCID: PMC5766251. 2018;14(1): e1006810.
   PubMed Web of Science ®Google Scholar
• Kinnear E, Lambert L, McDonald JU, et al. Erratum: airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunol. 2018. Jan. 11(1):290. Epub 2017 Aug 30. Erratum for: Mucosal Immunol. 2018 Jan; 11( 1): 249-256. PMID: 28853440.
   PubMed Web of Science ®Google Scholar
• Welliver TP, Reed JL, Welliver RC.Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J. 2008. 27. 10 Suppl): S92-6. PMID: 18820587.
   PubMed Web of Science ®Google Scholar
• Singleton R, Etchart N, Hou S, et al. Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol. 2003;77(21):11303–11311. PMID: 14557616; PMCID: PMC229280.
   PubMed Web of Science ®Google Scholar
• Habibi MS, Jozwik A, Makris S, et al. Mechanisms of severe acute influenza consortium investigators. impaired antibody-mediated protection and defective iga b-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med. 2015;191(9):1040–1049. PMID: 25730467; PMCID: PMC4435460.
   PubMed Web of Science ®Google Scholar
• Piedra PA, Hause AM, Aideyan L, et al. Respiratory syncytial virus (RSV): neutralizing antibody, a correlate of immune protection. Ra T, Pa J, editors. Human respiratory syncytial virus. Springer: New York. 2016. Vol. 1442. 77–91.
   Google Scholar
• Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991;163(4):693–698.
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes E, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329(21):1524–1530.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis. 1998;177(2):463–466.
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr. 1981;98(5):708–715. PMID: 7229749.
   PubMed Web of Science ®Google Scholar
• Glenn GM, Smith G, Fries L et al., Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine Epub 2012 Nov 12. PMID: 23153449. 2013;31(3): 524–532.
   PubMed Web of Science ®Google Scholar
• Fries L, Shinde V, Stoddard JJ et al., Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immun Ageing PMID: 28413427; PMCID: PMC5389002. 2017;14(1): 8.
   PubMedGoogle Scholar
• Glenn GM, Fries LF, Thomas DN et al., A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (f) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis Epub 2015 Aug 10. PMID: 26259809. 2016;213(3): 411–422.
   PubMed Web of Science ®Google Scholar
• August A, Glenn GM, Kpamegan E et al., A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine Epub 2017 Jun 1. PMID: 28579233. 2017;35(30): 3749–3759.
   PubMed Web of Science ®Google Scholar
• Muňoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (f) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. J Infect Dis. 2019;220(11):1802–1815. PMID: 31402384.
   PubMed Web of Science ®Google Scholar
• Eberhardt CS, Blanchard-Rohner G, Lemaître B et al., Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis PMID: 26797213 PMCID: PMC4787611. 2016;62(7): 829–836.
   PubMed Web of Science ®Google Scholar
• Abu Raya B, Srugo I, Kessel A, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - A prospective study. Vaccine. 2014;32(44):5787–5793. PMID: 25173476.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Polack FP, Piedra PA, et al. Prepare study group. respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. PMID: 32726529; PMCID: PMC7299433. 2020;383(5):426–439.
   PubMed Web of Science ®Google Scholar